Hemogenyx Pharmaceuticals PLC Announces Sale and Conversion of Loan Notes; Installation complete

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR IN ANY JURISDICTION IN WHICH OFFERS OR SALE WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ADVERTISEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO PURCHASE SECURITIES IN ANY JURISDICTION. NEITHER THIS ADVERTISEMENT NOR ANYTHING CONTAINED HEREIN WILL BE BASED ON, OR BE RELIED ON, ANY OFFER OR COMMITMENT OF ANY KIND IN ANY JURISDICTION.

THIS AD CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596 / EU AS PART OF UNITED KINGDOM’S DOMESTIC LAW UNDER EUROPEAN UNION LAW 2018 (WITHDRAWAL) (” MAR”). AS OF THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

  • Mint Capital Facility terminated

  • Redemption, sale and conversion of loan notes into common shares

LONDON, UK / ACCESSWIRE / May 18, 2021 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group that develops new therapies and treatments for deadly blood diseases, today announces an agreement with Mint Capital Advisors Ltd (“Mint capital“) for the redemption and sale of the entire aggregate principal amount of £ 8,100,000 outstanding of the Convertible Unsecured Loan Notes issued to Mint on February 3, 2021 (the”February 2021 Loan Notes“).

The main terms of the agreement with Mint Capital are as follows:

  • No further convertible debt notes will or may be drawn under the convertible debt facility announced by the Company on November 17, 2020 (the “Establishment“);

  • The Company will reimburse £ 1,600,000 of the principal amount of the February 2021 loan notes at a price equal to 100%. principal (i.e. £ 1,600,000) (the “Redemption“);

  • Mint Capital will sell £ 6,500,000 of the principal amount of the February 2021 Loan Notes to the seats purchased by Peterhouse Capital Limited (the “Sale“). The markets have agreed to an immediate conversion of these loan notes into ordinary shares of 1 pence each in the capital of the Company (“Ordinary actions“) at a conversion price of 1.5 pence (the”Conversion“);

  • Following completion of the redemption and sale and subsequent conversion;

  • There will be no convertible loan notes in circulation;

  • There will be no outstanding conversion notices relating to the facility; and

  • The entire facility entered into with Mint and announced by the Company on November 18, 2020 will terminate.

The finalization of the buyback and sale is expected to take place on May 20, 2021.

The directors have determined that the repurchase and sale are in the best interests of the company and its shareholders. The Company will be able to maintain its level of operations while advancing its product candidates into clinical trials, of which updates will be provided to shareholders in due course.

Admission of New Ordinary Shares

A total of 433,333,333 New Ordinary Shares will be issued following the Conversion (the “New ordinary sharesA request will be made to the Financial Conduct Authority and the London Stock Exchange for the admission of the New Ordinary Shares to the standard segment of the Official List and to trading on the main market of the London Stock Exchange for listed securities. , respectively ( “AdmissionAdmission is expected to take place at 8:00 a.m. on or around May 26, 2021. The New Ordinary Shares will be classified pari passu with the existing issued ordinary shares of the Company.

Total voting rights

Following the admission, the Company will dispose of 979,749,321 Ordinary Shares of 1 pence each with voting rights. The Company does not hold any treasury shares. This figure can then be used by the shareholders of the Company as a denominator for the calculation by which they will determine whether they are required to notify their interest or a change of their interest in the share capital of the Company by virtue of financial conduct. Authority disclosure guidelines and transparency rules.

The person responsible for organizing the publication of this announcement on behalf of the company is Dr Vladislav Sandler, CEO and Co-Founder.

Ask for information:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, CEO and co-founder

head [email protected]

Peter Redmond, Director

[email protected]

SP Angel Corporate Finance LLP

Phone: +44 (0) 20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Phone: +44 (0) 20 7469 0930

Lucy Williams, Duncan Vasey and Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York at its state-of-the-art research center.

The Company is a preclinical biopharmaceutical group developing new drugs and treatments to treat blood and autoimmune diseases and to bring the healing power of bone marrow transplant to a greater number of patients suffering from life-threatening diseases otherwise incurable. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for new product development.

For more than 50 years, bone marrow transplants have been used to save the lives of patients with blood diseases. However, the risks of toxicity and death associated with the bone marrow transplant mean that the procedure is limited to use as a last resort. The company’s technology has the potential to enable many more patients with devastating blood diseases such as leukemia and lymphoma, as well as serious autoimmune diseases such as multiple sclerosis, aplastic anemia and heart disease. Systemic lupus erythematosus (lupus), to benefit from a bone marrow transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is authorized by the Financial Conduct Authority to act as the main information provider in the UK. General conditions relating to the use and distribution of this information may apply. For more information, please contact [email protected] or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

See the source version on accesswire.com:
https://www.accesswire.com/647863/Hemogenyx-Pharmaceuticals-PLC-Announces-Loan-Notes-Sale-Conversion-Facility-Terminated


Source link

About Kimberly Alley

Check Also

Julie Jason: Can student loans lead to financial education? | Julie jason

It is always a challenge to comment on legislation pending in Congress before it becomes …

Leave a Reply

Your email address will not be published. Required fields are marked *